Table 1. Baseline characteristics of the participants.
| Characteristic | Total (n=39) | Control (n=13) | Low dose (n=14) | High dose (n=12) | P |
|---|---|---|---|---|---|
|
Age, % | |||||
| <60 years | 25 (64%) | 9 (69%) | 8 (57%) | 8 (67%) | 0.840 |
| ⩾60 years | 14 (36%) | 4 (31%) | 6 (43%) | 4 (33%) | |
|
Sex, % | |||||
| Male | 15 (38%) | 4 (31%) | 7 (50%) | 4 (33%) | 0.601 |
| Female | 24 (62%) | 9 (69%) | 7 (50%) | 8 (67%) | |
|
Body mass index, % | |||||
| <25.0 kg m−2 | 7 (18%) | 3 (23%) | 2 (14%) | 2 (17%) | 0.884 |
| 25.0–29.9 kg m−2 | 12 (31%) | 5 (38%) | 4 (29%) | 3 (25%) | |
| ⩾30.0 kg m−2 | 20 (51%) | 5 (38%) | 8 (57%) | 7 (58%) | |
| Energy intake, kcal day−1 | 1735 (1270–1962) | 1800 (1233–2110) | 1776 (1483–2111) | 1632 (1196–1739) | 0.725 |
|
Cancer stage, % | |||||
| I | 5 (13%) | 1 (8%) | 2 (14%) | 2 (17%) | 0.999 |
| II | 14 (36%) | 5 (38%) | 5 (36%) | 4 (33%) | |
| III | 20 (51%) | 7 (54%) | 7 (50%) | 6 (50%) | |
| Chemotherapy, % | 28 (72%) | 10 (77%) | 10 (71%) | 8 (67%) | 0.906 |
|
Time since treatment, % | |||||
| ⩽12 months | 25 (64%) | 8 (62%) | 10 (71%) | 7 (58%) | 0.770 |
| >12 months | 14 (36%) | 5 (38%) | 4 (26%) | 5 (42%) | |
P-values are from the overall test of group differences. Data are median (interquartile range), or counts with percentages.